Betaglycan alters NFκB-TGFβ2 Cross talk to reduce survival of human granulosa tumor cells

Molecular Endocrinology

Volumn 27, Issue 3, 2013, Pages 466-479

  Bilandzic, Maree ^a   Chu, Simon ^a   Wang, Yao ^a   Tan, Han L ^a   Fuller, Peter J ^a   Findlay, Jock K ^a   Stenvers, Kaye L ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; CASPASE 3; CASPASE 7; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SHORT HAIRPIN RNA; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA2;

APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME REACTIVATION; FEMALE; GENE SILENCING; GRANULOSA CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; PATHOGENESIS; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GRANULOSA CELL TUMOR; HUMANS; MODELS, BIOLOGICAL; NF-KAPPA B; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA2;

EID: 84874526654     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1239     Document Type: Article

References (41)

1. Fotopoulou C, Savvatis K, Braicu EI, et al. Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome. Gynecol Oncol. 2010;119: 285-290.
2. Jamieson S, Fuller PJ. Molecular pathogenesis of granulosa cell tumors of the ovary. Endocr Rev. 2012;33:109-144.
3. Fuller PJ, Chu S. Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends Endocrinol Metab. 2004; 15:122-128.
4. Jamieson S, Fuller PJ. Management of granulosa cell tumour of the ovary. Curr Opin Oncol. 2008;20:560-564.
5. Pectasides D, Papaxoinis G, Fountzilas G, et al. Adult granulosa cell tumors of the ovary: a clinicopathological study of 34 patients by the Hellenic Cooperative Oncology Group (HeCOG). Anticancer Res. 2008;28:1421-1427.
6. Miller K, McCluggage WG. Prognostic factors in ovarian adult granulosa cell tumour. J Clin Pathol. 2008;61:881-884.
7. Wu MY, Hill CS. Tgf-α superfamily signaling in embryonic development and homeostasis. Dev Cell. 2009;16:329-343.
8. Bilandzic M, Stenvers KL. Betaglycan: a multifunctional accessory. Mol Cell Endocrinol. 2011;339:180-189.
9. Lopez-Casillas F, Payne HM, Andres JL, Massague J. Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol. 1994;124:557-568.
10. Lopez-Casillas F, Wrana JL, Massague J. Betaglycan presents ligand to the TGFβ signaling receptor. Cell. 1993;73:1435-1444.
11. Stenvers KL, Tursky ML, Harder KW, et al. Heart and liver defects and reduced transforming growth factor β2 sensitivity in transforming growth factor β type III receptor-deficient embryos. Mol Cell Biol. 2003;23:4371-4385.
12. Escalona RM, Stenvers KL, Farnworth PG, Findlay JK, Ooi GT. Reducing betaglycan expression by RNA interference (RNAi) attenuates inhibin bioactivity in LβT2 gonadotropes. Mol Cell Endocrinol. 2009;307:149-156.
13. Lewis KA, Gray PC, Blount AL, et al. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature. 2000;404:411-414.
14. Wiater E, Harrison CA, Lewis KA, Gray PC, Vale WW. Identification of distinct inhibin and transforming growth factor β-binding sites on betaglycan: functional separation of betaglycan co-receptor actions. J Biol Chem. 2006;281:17011-17022.
15. Wiater E, Lewis KA, Donaldson C, Vaughan J, Bilezikjian L, Vale W. Endogenous betaglycan is essential for high-potency inhibin antagonism in gonadotropes. Mol Endocrinol. 2009;23:1033-1042.
16. Wiater E, Vale W. Inhibin is an antagonist of bone morphogenetic protein signaling. J Biol Chem. 2003;278:7934-7941.
17. Li Q, Graff JM, O'Connor AE, Loveland KL, Matzuk MM. SMAD3 regulates gonadal tumorigenesis. Mol Endocrinol. 2007; 21:2472-2486.
18. Looyenga BD, Hammer GD. Genetic removal of Smad3 from inhibin-null mice attenuates tumor progression by uncoupling extracellular mitogenic signals from the cell cycle machinery. Mol Endocrinol. 2007;21:2440-2457.
19. Pangas SA, Li X, Umans L, et al. Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice. Mol Cell Biol. 2008;28:248-257.
20. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A. α-Inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature. 1992;360:313-319.
21. Bilandzic M, Chu S, Farnworth PG, et al. Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells. Mol Endocrinol. 2009;23:539-548.
22. Lobb DK. Expression and actions of transforming growth factors during human follicular development. Fertil Steril. 2009;92:1080-1084.
23. Sanchez-Capelo A. Dual role for TGF-β1 in apoptosis. Cytokine Growth Factor Rev. 2005;16:15-34.
24. Chu S, Nishi Y, Yanase T, Nawata H, Fuller PJ. Transrepression of estrogen receptor β signaling by nuclear factor-κB in ovarian granulosa cells. Mol Endocrinol. 2004;18:1919-1928.
25. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κBas the matchmaker. Nat Immunol. 2011;12:715-723.
26. Criswell TL, Arteaga CL. Modulation of NFκB activity and Ecadherin by the type III transforming growth factor β receptor regulates cell growth and motility. J Biol Chem. 2007;282:32491-32500.
27. Criswell TL, Dumont N, Barnett JV, Arteaga CL. Knockdown of the transforming growth factor-β type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Res. 2008;68:7304-7312.
28. You HJ, How T, Blobe GC. The type III transforming growth factor-β receptor negatively regulates nuclear factor βB signaling through its interaction with β-arrestin2. Carcinogenesis. 2009;30: 1281-1287.
29. Jamieson S, Butzow R, Andersson N, et al. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Mod Pathol. 2010;23:1477-1485.
30. Shah SP, Kobel M, Senz J, et al. Mutation of FOXL2 in granulosacell tumors of the ovary. N Engl J Med. 2009;360:2719-2729.
31. Steinmetz R, Wagoner HA, Zeng P, et al. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol Endocrinol. 2004;18:2570-2582.
32. Chu S, Alexiadis M, Fuller PJ. Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors. Gynecol Oncol. 2008;108:182-190.
33. Nishi Y, Yanase T, Mu Y, et al. Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology. 2001;142:437-445.
34. van den Berg-Bakker CA, Hagemeijer A, Franken-Postma EM, et al. Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features and cytogenetics. Int J Cancer. 1993;53:613-620.
35. Sarraj MA, Chua HK, Umbers A, Loveland KL, Findlay JK, Stenvers KL. Differential expression of TGFBR3 (betaglycan) in mouse ovary and testis during gonadogenesis. Growth Factors. 2007;25: 334-345.
36. Sarraj MA, Escalona RM, Umbers A, et al. Fetal testis dysgenesis and compromised Leydig cell function in Tgfbr3 (β-glycan) knockout mice. Biol Reprod. 2010;82:153-162.
37. Walker KA, Sims-Lucas S, Caruana G, et al. Betaglycan is required for the establishment of nephron endowment in the mouse. PLoS One. 2011;6:e18723.
38. Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-β signaling. J Cell Biochem. 2007;101:9-33.
39. Roberts AB, Wakefield LM. The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci U S A. 2003;100: 8621-8623.
40. Inman GJ, Nicolas FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62:65-74.
41. Gong X, McGee EA. Smad3 is required for normal follicular follicle-stimulating hormone responsiveness in the mouse. Biol Reprod. 2009;81:730-738.